Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 ...

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals IONS has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...

Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company’s revenue was up 10.9% compared to the same quarter last year.

A month has gone by since the last earnings report for Ionis Pharmaceuticals (IONS). Shares have added about 5.5% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $183.00. The company’s s ...

Nanoscope Therapeutics Inc., a biotech company pioneering gene-agnostic therapies to restore vision in blind patients suffering from retinal degenerative diseases, today announced its participation in ...

Ionis Pharmaceuticals (NASDAQ:IONS), a biotechnology company specializing in RNA-targeted therapeutics with a market capitalization of $5.32 billion, stands at a critical juncture as it navigates ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate ...

IQVIA , a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's ...

Ionis Pharmaceuticals (NASDAQ:IONS), a biotechnology company specializing in RNA-targeted therapeutics with a market capitalization of $5.32 billion, stands at a critical juncture as it navigates a ...